Currently out of the existing stock ratings of Marc Frahm, 7 are a BUY (53.85%), 6 are a HOLD (46.15%).

Marc Frahm

Work Performance Price Targets & Ratings Chart

Analyst Marc Frahm, currently employed at TD COWEN, carries an average stock price target met ratio of 72.22% that have a potential upside of 21.12% achieved within 215 days. Previously, Marc Frahm worked at COWEN.

Marc Frahm’s has documented 26 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on INCY, yte at 10-Feb-2025.

Wall Street Analyst Marc Frahm

Analyst best performing recommendations are on TBPH (THERAVANCE BIOPHARMA).
The best stock recommendation documented was for TBPH (THERAVANCE BIOPHARMA) at 9/15/2021. The price target of $8 was fulfilled within 23 days with a profit of $1.23 (18.17%) receiving and performance score of 7.9.

Average potential price target upside

of $19.77 (34.04%) on INCY (YTE).
of $2.39 (28.21%) on TBPH (THERAVANCE BIOPHARMA).
of $0.4 (1.12%) on IMGO (IMAGO BIOSCIENCES).

TBPH Theravance Biopharma IMGO Imago Biosciences DAWN Day One Biopharmaceuticals INCY yte XLO Xilio Development SANA Sana Biotechnology BPMC Blueprint Medicines Corp CNST Constellation Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Douglas Tsao (HC WAINWRIGHT)